Treating Atopic Dermatitis: Moving from Symptoms to Underlying Pathology

Target Audience

This activity has been designed to meet the educational needs of dermatologists, allergists, immunology specialists, internists and primary care providers including physicians, nurse practitioners, physician assistants and other healthcare providers responsible for the diagnosis, treatment, or management of patients with atopic dermatitis. No prerequisites required.

Program Overview

Atopic dermatitis (AD) is a chronic, pruritic, inflammatory skin disease associated with a heterogeneous presentation and clinical course. There is no standard definition of AD severity. Rather, AD severity encompasses the converging effects of the intensity and extent of lesions, chronicity and flares, intensity of itch, pain, sleep disturbance, mental health symptoms, and impact on activities of daily living. Unfortunately, there are neither simple and validated severity assessments that are feasible for clinical practice, nor a single objective assessment or patient-reported outcome measure that fully captures all of these aspects of disease severity. Current treatments for patients with AD focus on topical therapy for mild-to-moderate AD and oral agents for patients with moderate-to-severe AD; fortunately, for adults with severe AD, biologic therapy is now available. The unique interactive infographics in this activity will review 3 important studies that address some of these barriers: Defining treatment success outside of clinical study endpoints, the relationship between skin pain and quality of life, and using a simplified, patient-reported approach to assessing disease severity.


The goal of this activity is to provide healthcare providers responsible for the diagnosis, treatment, or management of patients with AD with a greater insight into the different manifestations of AD symptoms and how they impact quality-of-life and patients’ assessment of disease severity and treatment success.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  • RECOGNIZE the latest science on the pathogenesis of AD and the related treatment implications.
  • INTERPRET patient-reported outcomes and how they can affect definitions of efficacy.
  • TRANSLATE patient-reported outcomes into improved management strategies.

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Relationship Identified With:
Linda Stein-Gold, MD Consultant/Advisor: LEO Pharma Inc, Medimetrix Group Inc, Pfizer Inc, and Sanofi-Regeneron.
Research Grant: LEO Pharma Inc, Pfizer Inc, and Valeant Pharmaceuticals International Inc.
Speakers’ Bureau: LEO Pharma Inc, Pfizer Inc, Sanofi-Regeneron, and Valeant Pharmaceuticals International Inc; Spouse: Valeant Pharmaceuticals International Inc.


Sandy Breslow; Alison Kemp; Bernard M. Abrams, MD; Daniel Guinee; Mary Gabb, MS; and, Lisa Mangione hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by independent educational grants from Sanofi Genzyme and Regeneron Pharmaceuticals.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education ASiM CE LLC.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and ASiM CE LLC, The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For all CME inquiries or special needs, please contact

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, ASiM CE LLC, and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

*Any and all written, or graphic representation of the information presented in Abstracts 6823 (data from: Vakharia et al. Allergy. 2018.), Abstract 6713 (data from: Vakharia et al. Ann Allergy Asthma Immunol. 2017), and Abstract 6848, presented at AAD 2018 are for educational purposes only and are entirely non-promotional.

Method of participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

Release date: August 22, 2018
Expiration date: August 21, 2019